MNK Mallinckrodt plc

-0.02  -0%
Previous Close 8.42
Open 8.56
Price To Book 0.23
Market Cap 704,036,088
Shares 83,813,820
Volume 4,063,987
Short Ratio 7.83
Av. Daily Volume 3,368,424

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be completed 2H 2019.
Hepatorenal syndrome (HRS) Type 1
CRL issued August 22, 2018.
Phase 3 enrolment to stop following interim analysis February 20, 2019.
UVADEX (methoxsalen) and Therakos
Acute Graft Versus Host Disease
Phase 2 commencement of enrollment announced August 2, 2018.
Duchenne Muscular Dystrophy
Approved April 30, 2015.
Phase 3 completion of enrolment announced April 12, 2019 with top-line data due by the end of 2019.
StrataGraft skin tissue
Deep partial thickness severe burns - skin defects
Phase 2 trial ongoing.
StrataGraft skin tissue
Full thickness severe burns - skin defects
Phase 3 trial did not show a statistically significant separation from placebo.
Niemann-Pick Disease
Phase 3 commencement of enrolment announced December 21, 2018. Interim analysis 4Q 2019 with completion due 2020.
Inhaled Xenon Gas Therapy
Post-cardiac arrest
CRL issued December 12, 2018.
Phase 3 data released May 7, 2019 did not meet primary endpoint.
Familial Adenomatous Polyposis (FAP)
Phase 2 data due 1Q 2021.
H.P. Acthar Gel
Amyotrophic Lateral Sclerosis

Latest News

  1. Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium
  2. Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)
  3. The U.S. Gets Hundreds of Millions From Big Pharma in Co-Pay Settlements
  4. Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
  5. All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)
  6. Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
  7. See what the IHS Markit Score report has to say about Mallinckrodt Plc.
  8. Mallinckrodt Down After Agreement with DOJ for Litigation
  9. Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?
  10. Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies
  11. Mallinckrodt's stock falls after it expects to pay more than $15 million to resolve DOJ investigation
  12. Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation Activities
  13. RM LAW Announces Investigation of Mallinckrodt plc
  14. Mallinckrodt Stock is Falling Because the Wheels Might ‘Finally Come Off’
  15. Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference
  16. Cara Shares Up on Positive Phase III Data for Itchiness Drug
  17. Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
  18. Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)
  19. Mallinckrodt's Amitiza to stay with branded business after spin-off